SCHEMBL4989140

SCHEMBL4989140

CC(CNC(=O)[CH]c1ccccc1)C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.40
BCAT2 O15382 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KMT2A Q03164 2/20 0.37
APAF1 O14727 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37
MMP1 P03956 2/20 0.36
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
EGFR P00533 2/20 0.35
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243719 0.79 KMT2A (0.41) KMT2AALDH1A1CYP2C19CYP3A4CYP2C9
SCHEMBL5664722 0.79 ALDH1A1 (0.40) KMT2AALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL4198308 0.76 TDP1 (0.44) HTTTDP1KMT2AALDH1A1CYP2C19
SCHEMBL4203722 0.75 HTT (0.45) HTTTDP1KMT2AMMP1MMP2
SCHEMBL3638056 0.74 SLC6A19 (0.49) KMT2AALDH1A1MMP1MMP2MMP9
SCHEMBL4201387 0.72 KMT2A (0.47) HTTKMT2AALDH1A1MMP1MMP2
SCHEMBL7382770 0.72 BCAT2 (0.42) BCAT2APAF1MTNR1AMTNR1B
SCHEMBL4984429 0.72 KMT2A (0.48) HTTKMT2AMMP1MMP2MMP9
SCHEMBL7220257 0.71 EGFR (0.54) KMT2AALDH1A1MMP1MMP2MMP9
SCHEMBL4986397 0.71 KMT2A (0.54) HTTTDP1KMT2AALDH1A1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468378-B2 Substituted quinoline compounds PFIZER INC. (US) 2008-12-23 US disclosed
US-7393958-B2 Triamide-substituted heterobicyclic compounds PFIZER, INC. (US) 2008-07-01 US disclosed
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 US disclosed
US-20070093525-A1 Triamide-substituted heterobicyclic compounds PFIZER INC 2007-04-26 US disclosed
EP-1716137-A1 SUBSTITUTED QUINOLINE COMPOUNDS Pfizer Products Incorporated (US) 2006-11-02 EP disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 US disclosed
US-20050234099-A1 Substituted quinoline compounds PFIZER INC 2005-10-20 US disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234099-A1 Substituted quinoline compounds APOB, APOL1, MTPN HTT 526/4885BCAT2 2337/4885TDP1 2012/4885
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 HTT 798/4885BCAT2 1776/4885TDP1 1722/4885
US-20070093525-A1 Triamide-substituted heterobicyclic compounds APOB, MTPN, CTRB1 HTT 798/4885BCAT2 1776/4885TDP1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.